Clinical Trial Detail

NCT ID NCT02109627
Title Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors C. Babis Andreadis
Indications

acute myeloid leukemia

Therapies

Cytarabine + Ficlatuzumab

Age Groups: adult

No variant requirements are available.